Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse.

A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in... http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Leukemia Research Pubmed

A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse.

Loading next page...
 
/lp/pubmed/a-phase-ii-study-of-bcl-2-antisense-oblimersen-sodium-combined-with-CTinJQW0h1

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
0145-2126
DOI
10.1016/j.leukres.2005.10.025
pmid
16730060

Abstract

Journal

Leukemia ResearchPubmed

Published: Sep 19, 2007

There are no references for this article.